Aileron Therapeutics Inc - ALRN Quarterly EPS earnings growth

Corporate company logo of Aileron Therapeutics Inc (ALRN)

The viability of Aileron Therapeutics (ALRN) relies on access to capital and the results of specialized oncology research. This quarterly earnings per share chart illustrates the trend of fundamental outcomes, where the value is recorded at 70.30. The efficiency of developing targeted therapies is increasing through the use of robotic systems and AI. The company is currently focusing on R&D, seeking partners to license its assets.

aileronrx.com (ALRN) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Aileron Therapeutics

- share price and consensus valuation forecast:
Fundamental company valuation:Aileron Therapeutics Inc - ALRN
Flagship merchandise of Aileron Therapeutics, Inc.

This indicator measures the dynamics of net earnings per share, allowing for an assessment of the business's ability to scale profitability relative to operating expenses and inflationary pressure on payroll. By analyzing the quarterly growth rate of earnings per share, an investor can determine how effectively laboratory robotics and AI implementation at Aileron Therapeutics (ALRN) are reducing routine costs, transforming technological automation into tangible financial results.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ELVN (Enliven Therapeutics, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share growth for the trailing year Relay Pharma|Nurix Therapeutics Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Biosciences|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|GLUE: Year-over-year earnings per share growth rate for the last twelve months|CGEM (cullinanoncology.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immuneering Inc. IMRX|Quarterly EPS earnings growth CCCC|Black Diamond Therapeutics - Year-over-year earnings per share growth for the last 12 months|Repare Therapeutics Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months PMVP|KPTI: Year-over-year net earnings per share growth for the last 12 months|propanc.com - Year-over-year earnings per share growth rate for the last twelve months|BGMS: Quarterly EPS earnings growth|Aadi Bioscience Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)